Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave

Inclusion Criteria: * Healthy volunteers: * Person who is ≥ 18 years old and ≤ 70 years old * Subject without neurological history * Subject without psychiatric history in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Subject having read and understood the newsletter and signed the consent form * Subject affiliated to a social security scheme. * Subject capable of understanding spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal. Patients with drug-resistant bipolar anhedonic depression: * Patient whose age is ≥ 18 years and ≤ 70 years. * Patient with depression meeting DSM-5 criteria (Appendix 4) evolving in the context of bipolar disorder. * Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification. * Patient with an SHAPS anhedonia score greater than 5/14. * Patient with no other psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Stable lithium treatment in the 7 days preceding the inclusion visit. * Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit. * Patient having a normal neurological examination. * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal.Patient dont l'âge est ≥ 18 ans et ≤ 70 ans. Patients with drug-resistant bipolar depression of the non-anhedonic type: * Patient whose age is ≥ 18 years and ≤ 70 years. * Presence of a depression meeting the criteria of DSM-5 (Annex 4) evolving in the context of bipolar disorder. * Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification. * Patient with SHAPS anhedonia score less than or equal to 3/14. * Absence of another psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Stable lithium treatment in the 7 days preceding the inclusion visit. * Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit. * Patient having a normal neurological examination. * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months. Patients with Parkinson's disease : * Patient whose age is ≥ 18 years and ≤ 70 years. * Patient with idiopathic Parkinson's disease as defined by the diagnostic criteria of the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) (Annex 8). * Patient with Parkinson's disease stage less than 3 (mild or moderate severity) according to the classification of Hoehn \& Yahr (Annex 7). * Patient treated with L-DOPA associated with a dopa-decarboxylase inhibitor (DDC) and who has not changed antiparkinsonian treatment for at least 1 month before the inclusion visit. * Patient with no neurological disorders other than those induced by Parkinson's disease. * Patient without depression defined by a score less than or equal to 8 on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Annex 10). * Patient with no psychiatric pathology at the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9). * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of childbearing age with effective contraception as defined by the WHO, for at least three months. Exclusion Criteria: * Healthy volunteers: * Person with a psychiatric disorder in the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9). * Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Existence of a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with drug-resistant bipolar anhedonic depression: * Patient with depression with psychotic characteristics. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2). * Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with drug-resistant bipolar depression of the non-anhedonic type: * Pa Patient with depression with psychotic characteristics. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2). * Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with Parkinson's disease: * Patient with depression. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Severe form of Parkinson's disease with a Hoehn and Yhar upper or equal 4 (Annex 7). * Patient with other neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine.